<DOC>
	<DOCNO>NCT00575471</DOCNO>
	<brief_summary>The purpose study assess efficacy response rivoglitazone HCl change HbA1c 12 week treatment patient type 2 diabetes .</brief_summary>
	<brief_title>Placebo Controlled Dose-Response Study Rivoglitazone Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>type 2 diabetes mellitus HbA1c &gt; 6.5 % &lt; 10 % FPG &gt; 126 mg/dL ( 7mmol/L ) &lt; 270 mg/dL ( 15 mmol/L ) history type 1 diabetes history ketoacidosis current insulin therapy Cpeptide &lt; 0.5ng/mL impair hepatic function CHF history CHF ( NYHA stage I IV ) uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>rivoglitazone HCl</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>peroxisome proliferator-activated receptor gamma ( PPARgamma )</keyword>
	<keyword>diabetes mellitus , type 2</keyword>
</DOC>